Health Care Flat on Biotech, Obesity-Drug Hopes -- Health Care Roundup

Health-care companies were flat, hovering near all-time highs amid optimism about the biotech and obesity-drug niches.

In the first head-to-head test, Eli Lilly's Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk's Wegovy.

Shares of Eli Lilly rose, while Novo Nordisk slipped.

Brian Thompson, chief executive of UnitedHealth's insurance arm, was fatally shot outside a hotel in New York City in a targeted attack, police said.

Write to Rob Curran at [e-mail]

(END) Dow Jones Newswires

12-04-24 1821ET